Newbiologix launches advanced rAAV platform for gene therapy production
NewBiologix, a Swiss technology innovation company specializing in cell and gene therapy production solutions, has introduced its cutting-edge Xcell rAAV Production and Analytics Platform (Xcell ... Read More
Gamma Biosciences to sell Mirus Bio to Merck KGaA for $600m in key biotech deal
Merck KGaA, Darmstadt, Germany (XTRA:MRK), a leading global science and technology company, has agreed to acquire Mirus Bio from Gamma Biosciences for $600 million in ... Read More
Pfizer secures FDA approval for Hemophilia B gene therapy BEQVEZ
Pfizer Inc. (NYSE: PFE) announced a significant breakthrough in hemophilia treatment with the U.S. Food and Drug Administration's approval of BEQVEZ (fidanacogene elaparvovec-dzkt), a pioneering ... Read More
RTW Biotech Opportunities joins $160.5m Series C of Obsidian Therapeutics
RTW Biotech Opportunities Ltd, an investment company listed on the London Stock Exchange and specialized in the life sciences sector, is proud to announce its ... Read More
Merck announces over €300m investment in new bioprocessing center in South Korea
Merck has embarked on a monumental investment venture, injecting more than €300 million into the construction of a new Bioprocessing Production Center located in Daejeon, ... Read More
Ginkgo Bioworks acquires Proof Diagnostics to boost cell programming and biosecurity capabilities
Ginkgo Bioworks, a leader in cell programming and biosecurity, announced its acquisition of Proof Diagnostics, a trailblazer in life sciences tools, diagnostics, and computational discovery. ... Read More
Andelyn Biosciences, Armatus Bio to accelerate gene therapy for CMT1A
Andelyn Biosciences, Inc., a leading Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapy, has announced a significant partnership with Armatus Bio ... Read More
bluebird bio unveils US commercial strategy for LYFGENIA gene therapy
bluebird bio, Inc., a pioneer in the biotechnology industry, has announced the U.S. commercial infrastructure for LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel), an FDA-approved ... Read More
XyloCor reveals promising 12-month data from Phase 2 Trial of XC001
XyloCor Therapeutics, a clinical-stage biopharmaceutical company focusing on novel gene therapies for cardiovascular diseases, has revealed encouraging 12-month data from the Phase 2 section of ... Read More
Laurus Labs expands stake in Immunoadoptive Cell Therapy for Rs.80cr
Hyderabad-based pharmaceutical company Laurus Labs has announced a significant investment in Immunoadoptive Cell Therapy (lmmunoACT), an advanced cell and gene therapy firm. The deal, valued ... Read More